» Articles » PMID: 9558366

A Novel Fusion Between MOZ and the Nuclear Receptor Coactivator TIF2 in Acute Myeloid Leukemia

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1998 May 23
PMID 9558366
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

Chromosomal abnormalities of band 8p11 are associated with a distinct subtype of acute myeloid leukemia with French-American-British M4/5 morphology and prominent erythrophagocytosis by the blast cells. This subtype is usually associated with the t(8;16)(p11;p13), a translocation that has recently been shown to result in a fusion between the MOZ and CBP genes. We have cloned the inv(8)(p11q13), an abnormality associated with the same leukemia phenotype, and found a novel fusion between MOZ and the nuclear receptor transcriptional coactivator TIF2/GRIP-1/NCoA-2. This gene has not previously been implicated in the pathogenesis of leukemia or other malignancies. MOZ-TIF2 retains the histone acetyltransferase homology domains of both proteins and also the CBP binding domain of TIF2. We speculate that the apparently identical leukemia cell phenotype observed in cases with the t(8;16) and the inv(8) arises by recruitment of CBP by MOZ-TIF2, resulting in modulation of the transcriptional activity of target genes by a mechanism involving abnormal histone acetylation.

Citing Articles

The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency.

Sheridan M, Maqbool M, Largeot A, Clayfield L, Xu J, Moncaut N J Hematol Oncol. 2024; 17(1):91.

PMID: 39380002 PMC: 11462755. DOI: 10.1186/s13045-024-01610-0.


A MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes.

Smolko A, Sullivan D, Olsen S, Kang H, Whedon S, Baell J Proc Natl Acad Sci U S A. 2024; 121(26):e2405905121.

PMID: 38889153 PMC: 11214132. DOI: 10.1073/pnas.2405905121.


p160 nuclear receptor coactivator family members and their role in rare fusion‑driven neoplasms (Review).

Segovia D, Safaric Tepes P Oncol Lett. 2024; 27(5):210.

PMID: 38572059 PMC: 10988192. DOI: 10.3892/ol.2024.14343.


Alzheimer's Disease-Related Epigenetic Changes: Novel Therapeutic Targets.

Paniri A, Hosseini M, Akhavan-Niaki H Mol Neurobiol. 2023; 61(3):1282-1317.

PMID: 37700216 DOI: 10.1007/s12035-023-03626-y.


HEY1-NCOA2 expression modulates chondrogenic differentiation and induces mesenchymal chondrosarcoma in mice.

Tanaka M, Homme M, Teramura Y, Kumegawa K, Yamazaki Y, Yamashita K JCI Insight. 2023; 8(10).

PMID: 37212282 PMC: 10322689. DOI: 10.1172/jci.insight.160279.